Pharma

Recent developments

Oncology progress and deals

The FDA approved perioperative KEYTRUDA plus Padcev for MIBC. Frontline dMMR endometrial cancer showed PFS benefit in the KEYNOTE‑C93 Phase 3 trial. Next‑gen KRAS G12C inhibitor divarasib beat approved agents. GSK advanced targeted oncology via its Nuvalent acquisition. China’s ARTEMIS‑008 trial showed OS benefit for a B7‑H3 ADC.

Renal and infection updates

Roche/Genentech received FDA Priority Review for Gazyva/Gazyvaro in primary membranous nephropathy, supported by MAJESTY Phase III remission data. The CE‑marked Elecsys IGRA TB assay enables higher‑throughput latent‑TB screening on cobas analyzers with integrated automation for clinical labs.

Manufacturing capacity builds

Evonik will invest US$100 million at Tippecanoe Labs. WuXi Biologics’ MFG8 facility passed FDA Pre‑License Inspection for commercial biologics. AGC Biologics partnered with Pyramid Pharma Services to add US sterile fill‑finish. SPIE increased EPCMV reach via the nimeg ag acquisition.

Inputs and enabling tools

Brenntag will exclusively distribute Evonik REXIM GMP amino acids across most of Europe. Evonik and evitria introduced the eviCHO Expression Kit for rapid CHO‑based protein production. The EIB financed Orano Med’s ATEF thorium‑228 facility. Takeda and Indonesia plan a national plasma ecosystem for PDMPs.

Broader pipeline and outlook

Merck outlined HIV regimen and PrEP updates in its AIDS 2026 program overview. Novo Nordisk reported sustained haemophilia A control with denecimig (Mim8). Lilly prepared Alzheimer’s findings, including P‑tau217 blood assays. Johnson & Johnson raised 2026 guidance, citing Innovative Medicine growth.